Biology News
In-Vitro Toxicology Market, 2023 - GlobeNewswire (press release)


GlobeNewswire (press release)
Dublin, July 26, 2018 (GLOBE NEWSWIRE) -- The "In Vitro Toxicology Market" report has been added to ResearchAndMarkets.com's offering. The in vitro toxicity testing markets include methods and technologies used for toxicity testing of pharmaceuticals, ...
thehonestanalytics.com
theaerospacenews.com

A Life Remembered | UI biologist a maternal force in her field - Champaign/Urbana News-Gazette


Champaign/Urbana News-Gazette
URBANA — When Lori Raetzman interviewed for a position in the University of Illinois' School of Molecular and Cellular Biology more than a decade ago, she already knew of Professor Ann Nardulli's work as a researcher. But she had never had the ...

In a 'tour de force,' researchers image an entire fly brain in minute detail - Science Magazine


Science Magazine
“This data set—and the opportunities it creates—are … arguably one of the most important things to have happened in neurobiology recently,” says Rachel Wilson, a neurobiologist at Harvard University who was not involved in the new work. “Anyone in ...

AFT Pharmaceuticals - A New Force In Pharmaceuticals

Auckland - New Zealand

AFT Pharmaceuticals is a privately owned company with operations in both Australia and New Zealand. The company was founded in 1997 by Dr Hartley Atkinson.

AFT operates as a full service pharmaceutical company and also undertakes drug development activities including clinical trials. AFT has a growing portfolio of patented and niche pharmaceuticals which are in the process of being licensed for sale outside the Australasian market.

Related
Prolexys Pharmaceuticals, Inc.
United States

Mapping protein-protein interactions and identify new targets for drug discovery to treat cancer and cardiovascular disease. Explains technology platforms and aetology targeted, with FAQ, company alliances and management in Salt Lake City, Utah.

MultiTarget Pharmaceuticals
United States

Manufacturer of AquaPlasmid, a system for the isolation of pure plasmid DNA. The procedure is simpler than alkaline lysis, but the DNA prep is purer than those purified by anion exchange columns, in Salt Lake City, Utah, USA.

Alnylam Pharmaceuticals
United States

Develops novel therapeutics based RNAi. Provides overview of recent drug development programs. Includes company profile and technology information.

Calando Pharmaceuticals
United States

Company developing non-viral technologies for the therapeutic use of RNAi.

RXi Pharmaceuticals
United States

Discovery-stage biotechnology company pursuing the development of RNAi therapeutics for the treatment of neurodegenerative disease, diabetes and obesity.

Quantum Pharmaceuticals
United States

Provides drug discovery using computational technology to simulates intermolecular interactions.

United States

Develops and researches proprietary immunoregulatory compounds for treatment of autoimmune and cardiovascular disorders, inflammation and cancer. Provides information about products and technologies, as well as corporate and investment data. New Haven, CT.

Beximco Pharmaceuticals Ltd.
Bangladesh

Beximco Pharmaceuticals Ltd (BPL) is a leading manufacturer of pharmaceutical formulations and Active Pharmaceutical Ingredients (APIs) in Bangladesh. The company is one of the largest exporter of pharmaceuticals in the country and its state-of-the-art manufacturing facilities are certified by global regulatory bodies of Australia, European Union, Gulf nations, Brazil, among others. The company is consistently building upon its portfolio and curr

Square Pharmaceuticals Ltd.
Bangladesh

Our Mission is to produce and provide quality & innovative healthcare relief for people, maintain stringently ethical standard in business operation also ensuring benefit to the shareholders, stakeholders and the society at large. We view business as a means to the material and social wellbeing of the investors, employees and the society at large, leading to accretion of wealth through financial and moral gains as a part of the process of the

United States

Developing technologies for targeted delivery of RNAi using non-pathogenic bacteria to produce RNA Interference.